Vitamin B6 metabolism in women using oral contraceptives

Inhibition of human kynurenine aminotransferase isozymes by estrogen and its derivatives

The kynurenine aminotransferase (KAT) enzymes are pyridoxal 5′-phosphate-dependent homodimers that catalyse the irreversible transamination of kynurenine into kynurenic acid (KYNA) in the tryptophan metabolic pathway. Kynurenic acid is implicated in cognitive diseases such as schizophrenia, and several inhibitors have been reported that selectively target KAT-II as it is primarily responsible for kynurenic acid production in the human brain. Not only is schizophrenia a sexually dimorphic condition, but women that have schizophrenia have reduced estrogen levels in their serum. Estrogens are also known to interact in the kynurenine pathway therefore exploring these interactions can yield a better understanding of the condition and improve approaches in ameliorating its effects. Enzyme inhibitory assays and binding studies showed that estradiol disulfate is a strong inhibitor of KAT-I and KAT-II (IC₅₀: 291.5 μM and 26.3 μM, respectively), with estradiol, estradiol 3-sulfate and estrone sulfate being much weaker (IC₅₀ > 2 mM). Therefore it is possible that estrogen levels can dictate the balance of kynurenic acid in the brain. Inhibition assay results and modelling suggests that the 17-sulfate moiety in estradiol disulfate is very important in improving its potency as an inhibitor, increasing the inhibition by approximately 10–100 fold compared to estradiol.

A mathematical model of tryptophan metabolism via the kynurenine pathway provides insights into the effects of vitamin B-6 deficiency, tryptophan loading, and induction of tryptophan 2,3-dioxygenase on tryptophan metabolites

Vitamin B-6 deficiency is associated with impaired tryptophan metabolism because of the coenzyme role of pyridoxal 5'-phosphate (PLP) for kynureninase and kynurenine aminotransferase. To investigate the underlying mechanism, we developed a mathematical model of tryptophan metabolism via the kynurenine pathway. The model includes mammalian data on enzyme kinetics and tryptophan transport from the intestinal lumen to liver, muscle, and brain. Regulatory mechanisms and inhibition of relevant enzymes were included. We simulated the effects of graded reduction in cellular PLP concentration, tryptophan loads and induction of tryptophan 2,3-dioxygenase (TDO) on metabolite profiles and urinary excretion. The model predictions matched experimental data and provided clarification of the response of metabolites in various extents of vitamin B-6 deficiency. We found that moderate deficiency yielded increased 3-hydroxykynurenine and a decrease in kynurenic acid and anthranilic acid. More severe deficiency also yielded an increase in kynurenine and xanthurenic acid and more pronounced effects on the other metabolites. Tryptophan load simulations with and without vitamin B-6 deficiency showed altered metabolite concentrations consistent with published data. Induction of TDO caused an increase in all metabolites, and TDO induction together with a simulated vitamin B-6 deficiency, as has been reported in oral contraceptive users, yielded increases in kynurenine, 3-hydroxykynurenine, and xanthurenic acid and decreases in kynurenic acid and anthranilic acid. These results show that the model successfully simulated tryptophan metabolism via the kynurenine pathway and can be used to complement experimental investigations.

The effect of oral contraceptives on the apparent vitamin B6 status in some Sudanese women

1. In vitro activation of erythrocyte aspartate aminotransferase (EC 2.6.1.1) activity by pyridoxal phosphate was used to assess vitamin B6 nutritional status in forty Sudanese women taking combined, low-dose oral contraceptives (oestrogen-progestogen; OC) and in thirty healthy, non-pregnant women not taking OC. 2. Fourteen (35%) out of forty OC users showed apparent vitamin B6 deficiency. 3. Side-effects associated with OC were more common among the apparently vitamin-B6-deficient OC users than among OC users and non-OC users not deficient in vitamin B6.

Serum 25-hydroxycholecalciferol levels in women using oral contraceptives

A study has been made of the serum 25-hydroxycholecalciferol (25-HCC) levels in six groups of women. Significant differences were found between the one pregnant group and the two reference groups as well as between the one pregnant group and two of the three groups using oral contraceptives. No significant differences were found between the reference groups and the ones taking oral contraceptives with oestrogenic concentrations of 0.05 mg or 0.03 mg ethinyl oestradiol for more than one year. It can therefore be concluded that in contrast with most other vitamins, the serum 25-HCC levels are not influenced by the use of oral contraceptives with different oestrogenic concentrations, even over a long period of time.